U.S. Markets open in 3 mins

Analysts' Actions: ANR BMY CAT DIS

TheStreet Staff

Arch Coal ACI was upgraded at BMO Capital from underperform to market perform. $8 price target. Met coal fundamentals appear to be improving, BMO said.
Alpha Natural ANR was upgraded at BMO from underperform to market perform. $8 price target. Estimates were also increased, given the company's new guidance, BMO said.
Arotech ARTX upgraded to hold at TheStreet Ratings.
First PacTrust Bancorp BANC upgraded to buy at TheStreet Ratings.
BB&T BBT was upgraded at Bank of America/Merrill Lynch to buy. Stock is attractive, following a 15% pullback, BofA/Merrill said. $32 price target.
Berry Plastics BERY was initiated with an outperform rating at Wells Fargo. Company offers innovative products and can pay down debt, Wells Fargo said.
Bristol-Myers Squibb BMY was downgraded at BMO Capital to market perform from outperform. $37 price target. A number of pipeline setbacks this year, BMO Capital said.
Caterpillar CAT was downgraded at JP Morgan from overweight to neutral. $90 price target. Company has high inventory levels and faces lower mining spending, JP Morgan said.
Comerica CMA was upgraded at Citigroup from sell to neutral. $28 price target. Stock is down 11% over the past seven months, Citi said.
Disney DIS was upgraded at Citi from neutral to buy. $54 price target. Recent acquisitions should boost future growth, Citi said.
Garmin GRMN was downgraded at Goldman Sachs from neutral to sell. $34 price target. Company is seeing lower demand for personal navigation and fitness devices, Goldman said.
Hibbett Sports HIBB was upgraded at Needham from hold to buy. Stock is down about 15% from its recent highs, Needham said. $61 price target.
JC Penney JCP was downgraded at Credit Suisse from neutral to underperform. $15 price target. Estimates were also cut, as management is struggling to turn the business around, Credit Suisse said.
Johnson & Johnson JNJ was downgraded at Jefferies to hold from buy. $75 price target. Easy money has been made, Jefferies said.
Merck MRK was upgraded at BMO Capital to outperform from market perform. $50 price target. Positive data from two early-stage products, BMO Capital said.
Nelnet NNI was upgraded at Credit Suisse from neutral to outperform. $33 price target. Estimates were also boosted, given loan purchases and higher realized net interest margin, Credit Suisse said.
NYSE Euronext NYX was upgraded at Stifel Nicolaus from hold to buy. $27 price target. Stock is attractively valued at a 52-week low, Stifel Nicolaus said.
Telephone & Data TDS was upgraded at Citigroup from neutral to buy. $27 price target. Management is selling assets while it is faced with with increased competition, Citi said.
Tripadvisor TRIP was upgraded at Morgan Stanley from underweight to overweight. $41 price target. Company is changing its monetization strategy and remains leveraged to higher hotel shopper growth, Morgan Stanley said.
US Cellular USM was upgraded at Citigroup from neutral to buy. $42 price target. Wireless asset purchase should be accretive to shareholder value, Citi said.
Vertex Pharmaceuticals VRTX was downgraded at Credit Suisse from outperform to neutral. $48 price target. Company will likely see lower Incivek sales, Credit Suisse said.
Western Union WU was upgraded at DA Davidson to neutral from underperform. $13 price target. At current prices, downside appears minimal, DA Davidson said.


Ameren AEE estimates, target reduced at UBS. AEE estimates were cut through 2013, UBS said. Company is seeing slower usage trends. Neutral rating and new $32 price target.
Citigroup C added to US 1 List at BofA/Merrill. C was placed on the US 1 list, Bank of America/Merrill Lynch said. The company trades at a discount to its peers, but its recovery is clearly on track. $45 price target.
Celgene CELG target raised at Jefferies to $94, Jefferies said. Abraxane shows survival benefit. Buy rating.
Generac Holdings GNRC numbers raised at BMO. Shares of GNRC now seen reaching $42, BMO said. Estimates also increased on recent storm caused demand. Outperform rating.
Heartware HTWR estimates, target cut at UBS. Shares of HTWR now seen reaching $100, according to UBS. Estimates also reduced, given slower international growth and expected adoption of HVAD. Buy rating.
Medivation MDVN numbers raised at Jefferies. Shares of MDVN now seen reaching $62, Jefferies said. Estimates also raised on Xtandi beat. Buy rating.
Pfizer PFE numbers lowered at Jefferies. Shares of PFE now seen reaching $27, Jefferies said. Estimates also lowered on revenue miss. Buy rating.


Technology and Media sectors downgraded at Wells from market-weight to underweight, Wells Fargo said. The Media sector was also cut from Overweight to Market-weight. Groups are leveraged to slower business spending.
>To submit a news tip, email: tips@thestreet.com.


>>Microsoft's Windows 8: Why I Changed My Mind

>>FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs

Follow TheStreet on Twitter and become a fan on Facebook.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE. Sign up today to get e-mail alerts before every trade.